drugset

drugset / Trial / NCT05621551

Dapagliflozin Therapy In Cardiac Surgery

NCT05621551 ↗

Phase 4 Completed 178 enrolled China National Center for Cardiovascular Diseases

RandomizedParallel-groupSingle-blindTreatment

Summary

This randomized controlled trial is to assess the effects of perioperative dapagliflozin on type 2 diabetic patients undergoing cardiac surgery

Timeline

Start: 2022-11-11
Primary completion: 2024-06-01
Completion: 2025-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	—

Indications